<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2277</td>
<td>PRAMEing a Picture of Differentiation Therapy for AML?</td>
<td>Robert L. Redner</td>
</tr>
<tr>
<td>2280</td>
<td>Classifying MMR Variants: Time for Revised Nomenclature in Lynch Syndrome</td>
<td>Y. Nancy You and Eduardo Vilar</td>
</tr>
<tr>
<td>2283</td>
<td>New Strategies in Diagnosing Cancer in Thyroid Nodules: Impact of Molecular Markers</td>
<td>Yuri E. Nikiforov, Linwah Yip, and Marina N. Nikiforova</td>
</tr>
<tr>
<td>2289</td>
<td>U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma</td>
<td>Michael Axelson, Ke Liu, Xiaoping Jiang, Kun He, Jian Wang, Hong Zhao, Dubravka Kufirin, Todd Palmby, Zedong Dong, Anne Marie Russell, Sarah Mikinski, Patricia Keegan, and Richard Pazdur</td>
</tr>
<tr>
<td>2294</td>
<td>Molecular Pathways: Radiation-Induced Cognitive Impairment</td>
<td>Dana Greene-Schloesser, Elizabeth Moore, and Mike E. Robbins</td>
</tr>
<tr>
<td>2301</td>
<td>Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance</td>
<td>Antonia L. Pritchard and Nicholas K. Hayward</td>
</tr>
<tr>
<td>2310</td>
<td>Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma</td>
<td>Lipika Goyal, Mandal D. Muzumdar, and Andrew X. Zhu</td>
</tr>
<tr>
<td>2331</td>
<td>High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition</td>
<td>Elisabeth Wik, Even Birkenland, Jone Trovik, Henrica MJ. Werner, Erling A. Holvik, Siv Mjös, Camilla Krakstad, Kathrina Kusunmano, Karen Mauand, Ingunn M. Stefansson, Frederik Holst, Kjell Petersen, Anne M. Oyan, Ronald Simon, Karl H. Kalland, William Ricketts, Lars A. Akslen, and Helga B. Salvesen</td>
</tr>
</tbody>
</table>
Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia

Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma
Christina A. von Roemeling, Laura A. Marlow, Johnny J. Wei, Simon J. Cooper, Thomas R. Caulfield, Kevin Wu, Winston W. Tan, Han W. Tun, and John A. Copland

Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease
Suzanne E. Wardell, Erik R. Nelson, Christina A. Chao, and Donald P. McDonnell

Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Inga Hinrichsen, Angela Brierje, Jörg Trojan, Stefan Zeuzem, Mef Nilbert, and Guido Plotz

Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
Daniel W. Lin, Lisa F. Newcomb, Elissa C. Brown, James D. Brooks, Peter R. Carroll, Ziding Feng, Martin E. Gleave, Raymond S. Lance, Martin G. Sandra, Ian M. Thompson, John T. Wei, and Peter S. Nelson, for the Canary Prostate Active Surveillance Study Investigators
Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma
Assunta De Rienzo, William G. Richards, Beow Y. Yeap, Melissa H. Coleman, Peter E. Sugarbaker, Lucian R. Chirieac, Yaoyu E. Wang, John Quackenbush, Roderick V. Jensen, and Raphael Bueno

Tissue Redox Activity as a Hallmark of Carcinogenesis: From Early to Terminal Stages of Cancer
Rumiana Bakalova, Zhivko Zhelev, Ichio Aoki, and Tsuneo Saga

Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101
Thomas S.C. Ng, David Wert, Hargun Sohi, Daniel Procissi, David Colcher, Andrew A. Raubitschek, and Russell E. Jacobs

Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study
Jong-Lyel Roh, Xin Victoria Wang, Judith Manola, David Sidransky, Arlene A. Forastiere, and Wayne M. Koch

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonian Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, and Deborah Ricci

PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)
Lars Bullinger, Richard F. Schlenk, Marlies Götz, Ursula Botzenhardt, Susanne Hofmann, Anika C. Russ, Anna Babia, Lu Zhang, Vanessa Schneider, Konstanze Döhner, Michael Schmitt, Hartmut Döhner, and Jochen Greiner

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
Liang Xie, Xinying Su, Lin Zhang, Xiaolu Yin, Lili Tang, Xiuhua Zhang, Yanping Xu, Zeren Gao, Kunji Liu, Minhua Zhou, Beirong Gao, Daoping Shen, Lianhai Zhang, Jiafu Ji, Paul R. Gavine, Jingchuan Zhang, Elaine Kilgour, Xiaolin Zhang, and Qunsheng Ji

Characteristics of Lung Cancers Harboring NRAS Mutations
Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila, Christine M. Lovly, Xi Chen, Charles M. Rudin, Teresa Moran, David Ross Camidge, Cindy L. Vnencak-Jones, Lynne Berry, Yumei Pan, Hidehumi Sasaki, Jeffrey A. Engelman, Edward B. Garon, Steven M. Dubinett, Wilbur A. Franklin, Gregory J. Riely, Martin L. Sos, Mark G. Kris, Dora Dias-Santagata, Marc Ladanyi, Paul A. Bunn Jr, and William Pao
ABOUT THE COVER

Assembling of microRNA-loaded transferrin-conjugated-nanoparticles to target acute myeloid leukemia (AML) blasts. The nanoparticle core was composed of negatively charged microRNA molecules (miR) and positively charged polyethylenimine (PEI). Empty nanoparticles were composed of DOPE, linoleic acid, and DMG-PEG. After the loading of the PEI-miR core in the nanoparticles, transferrin-PEG-DSPE was inserted into the nanoparticle surface for specific targeting of leukemia blasts. The background depicts a cytospin of AML blasts derived from a mouse with AML treated with miR-loaded nanoparticles. For details, see the article by Huang and colleagues on page 2355 of this issue.

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org
Clinical Cancer Research

19 (9)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/9

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.